LLY catalysts
Catalysts and events linked to LLY, newest first.
Do these developments change your position?
Review LLY alongside your other holdings and identify which decision deserves attention first.
Review your initial audit before choosing ongoing portfolio scanning at $79/month.
DateCardAvg 5d
- 2026-09-12Eli Lilly Immunology Revenue Reaches $2.6B in H1 2026 to Diversify Beyond GLP-1LLY
- 2026-09-12Eli Lilly immunology division generates $2.6B in H1 revenue (+9% YoY) via M&A pushLLY
- 2026-09-12Eli Lilly immunology sales reach $2.6B in H1 2026, rising 9% YoYLLY
- 2026-09-12Eli Lilly posts $2.6B in H1 immunology revenue, up 9% YoYLLY
- 2026-09-12Eli Lilly posts $2.6B in H1 immunology revenue, up 9% YoYLLY
- 2026-09-12Eli Lilly immunology revenue rises 9% in H1 2026 to $2.6B on DICE and Morphic M&ALLY
- 2026-09-12Eli Lilly Immunology Division Generates $2.6B in H1 2026 RevenueLLY
- 2026-09-12Eli Lilly H1 Immunology Revenue Hits $2.6B via Taltz and M&A PipelineLLY
- 2026-09-12Eli Lilly immunology sales reach $2.6B in H1 2026 led by Taltz, Ebglyss, and OmvohLLY
- 2026-09-12Eli Lilly immunology sales reach $2.6B in H1 2026 led by Taltz, Ebglyss, and OmvohABBV LLY
- 2026-09-12Eli Lilly Immunology Division Reaches $2.6B in H1 2026 on Taltz and New LabelsABBV LLY
- 2026-09-12Eli Lilly immunology sales reach $2.6B in H1 2026, rising 9% YoYABBV LLY
- 2026-09-12Eli Lilly H1 Immunology Revenue Hits $2.6B via Taltz and M&A PipelineABBV LLY
- 2026-09-12Eli Lilly immunology revenue rises 9% in H1 2026 to $2.6B on DICE and Morphic M&ALLY
- 2026-09-12Eli Lilly immunology revenue reaches $2.6B in H1 2026 on Taltz and M&A assetsABBV LLY
- 2026-09-12Eli Lilly immunology division generates $2.6B in H1 revenue (+9% YoY) via M&A pushABBV LLY
- 2026-09-12Eli Lilly Immunology Revenue Reaches $2.6B in H1 2026 to Diversify Beyond GLP-1LLY
- 2026-09-12Eli Lilly posts $2.6B in H1 immunology revenue, up 9% YoYLLY
- 2026-09-12Eli Lilly Immunology Revenue Reaches $2.6B in H1, Growing 9% Year-Over-YearLLY
- 2026-09-12Eli Lilly Immunology Division Reaches $2.6B H1 Sales on 9 Percent GrowthABBV LLY
- 2026-09-12Eli Lilly Immunology Division Generates $2.6B in H1 2026 RevenueABBV LLY
- 2026-09-08Eli Lilly Accelerates Biotech Acquisitions to Dilute GLP-1 Revenue ConcentrationLLY XBI-4.88%
- 2026-09-08Eli Lilly Accelerates Biotech Acquisitions to Dilute GLP-1 Revenue ConcentrationLLY XBI-4.88%
- 2026-09-08Eli Lilly Accelerates Biotech Acquisitions to Dilute GLP-1 Revenue ConcentrationLLY XBI-4.88%
- 2026-09-06Atopic Dermatitis Biopharma Market Projected to Reach $33.4B by 2035 at 7.7% CAGRABBV LLY REGN
- 2026-09-06Atopic Dermatitis Market Projected to Reach $33.4B by 2035 at 7.7% CAGRABBV LLY
- 2026-09-06Atopic Dermatitis Market Projected to Reach $33.42B by 2035 on Biologics DemandABBV LLY REGN
- 2026-09-06Atopic Dermatitis Market Projected to Reach $33.4B by 2035 at 7.7% CAGRABBV LLY REGN
- 2026-09-06Atopic Dermatitis Biopharma Market Projected to Reach $33.4B by 2035 at 7.7% CAGRABBV LLY REGN
- 2026-09-03Nxera Pharma Receives $8.6M Milestone From Eli Lilly Subsidiary Centessa on OX2R AgonistLLY
- 2026-09-03Nxera Pharma Secures $8.6M Milestone from Lilly Subsidiary CentessaLLY
- 2026-09-03Nxera Earns $8.6M Milestone from Eli Lilly Subsidiary on Late-Stage OX2R ProgressLLY
- 2026-09-03Nxera Pharma Secures $8.6M Milestone from Lilly Subsidiary CentessaLLY
- 2026-09-03Nxera Pharma Secures $8.6M Milestone from Centessa on OX2R Agonist ProgressLLY
- 2026-09-03Nxera Pharma Receives $8.6M Milestone from Eli Lilly Subsidiary CentessaLLY
- 2026-09-03Nxera Earns $8.6M Milestone from Eli Lilly Subsidiary on Late-Stage OX2R ProgressLLY
- 2026-09-03Nxera Pharma Receives $8.6M Milestone From Eli Lilly Subsidiary Centessa on OX2R AgonistLLY
- 2026-09-01NexLife Launches Flat-Rate $119-$169 Compounded GLP-1 Programs Across DosesLLY NVO-1.24%
- 2026-09-01NexLife Expands Compounded GLP-1 Plans With Flat $119-$169 Monthly TiersLLY NVO-1.24%
- 2026-09-01NexLife Expands Compounded GLP-1 Pricing at $119-$169 Flat Monthly FeeLLY NVO-1.24%
- 2026-09-01NexLife Expands Compounded GLP-1 Plans With Flat $119-$169 Monthly TiersLLY NVO-1.24%
- 2026-09-01NexLife Launches Flat-Rate $119-$169 Compounded GLP-1 Programs Across DosesLLY NVO-1.24%
- 2026-08-31Novo Nordisk Advances Oral Wegovy and Implant Program Against Eli Lilly LeadLLY NVO VANI-0.38%
- 2026-08-31Novo Nordisk advances oral Wegovy and Vivani implant partnership in GLP-1 raceLLY NVO VANI-0.38%
- 2026-08-31Novo Nordisk advances Wegovy pill formulation and Vivani implant partnershipLLY NVO VANI-0.38%
- 2026-08-31Novo Nordisk Introduces Oral Wegovy and Vivani Implant PartnershipLLY NVO VANI-0.38%
- 2026-08-30Eli Lilly Posts 45% Top-Line Growth but Faces Two-Thirds GLP-1 Revenue ConcentrationLLY
- 2026-08-30Eli Lilly GLP-1 Portfolio Generates Two-Thirds of Total Revenue Amid 45% Top-Line GrowthLLY
- 2026-08-30Novo Nordisk Deploys Oral Wegovy and Vivani Implant Delivery in GLP-1 RaceLLY NVO VANI+2.17%
- 2026-08-30Eli Lilly Posts 45% Top-Line Growth but Faces Two-Thirds GLP-1 Revenue ConcentrationABBV LLY
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.